search icon
      blog search icon

      Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment - Stocks Telegraph

      By Shimrez Hyder

      Published on

      July 28, 2021

      10:12 AM UTC

      Sintx Technologies, Inc. (SINT) Stock Undergoes Volatility Following News of First FleX SN-PEEK Shipment - Stocks Telegraph

      Sintx Technologies, Inc. (SINT) stock prices were up 11.04% as of the market closing on July 27th, 2021, bringing the price per share up to USD$1.71 at the end of the trading day. Subsequent premarket fluctuations saw the stock drop by 5.85%, bringing it down to USD$1.61.

      FleX SN-PEEK Shipments

      July 27th, 2021 saw SINT stock announce the first shipment of FleX SN-PEEK, its new product that is designed to be used in orthopedic implants. The company’s proprietary product commenced being shipped on July 20th, 2021, combining the singular bioactivity of silicon nitride with the properties of Zeniva PEEK, which was supplied by Solvay.

      About FleX SN-PEEK

      The composite material has been deemed to have a myriad of applications, ranging from spine surgery to joint replacements to craniomaxillofacial medical devices. On the basis of data collected by SINT stock on silicon nitride, FleX SN-PEEK is expected to facilitate faster bone healing, improved radiographic imaging, avoid metal ion release in the body, and have broad-spectrum resistance to infection as compared to PEEK in isolation.

      Advantages of FleX SN-PEEK

      The commencement of the shipping of SINT stock’s FleX SN-PEEK is a major milestone for the company. It continues to allocate resources to leverage the osteogenic and antipathogenic properties of silicon nitride for biomedical applications. The company is confident that the product differentiates itself as being superior with many unmatched benefits. Zaniva PEEK is a biomaterial that has been determined to have many advantages, signaled by its worldwide use. The advantages include favorable material modules, ease of manufacturing, established clinical record, as well as a track record of use in orthopedics.

      SINT Stock Healthcare Scope

      The combination of PEEK with silicon nitride’s osteogenic and antipathogenic properties gives rise to a superior product, FleX SN-PEEK. The catalogue of FleX SN-PEEK products provides access to new biomedical areas like craniomaxillofacial, and foot osteotomy and fusion. The proprietary technology serves to address a large unmet need stemming from surgeons constantly on the lookout for materials and procedures that result in improved outcomes with mitigated complications.

      Future Outlook for SINT

      Armed with the success of the first delivery of its proprietary technology, SINT stock is poised to capitalize on the continued development of FleX SN-PEEK. The company is keen to expand and consolidate its market footprint in order to continue its trajectory of success. Investors are hopeful that management will be able to allocate resources so as to ensure maximum gains in shareholder value.

      More From Stocks telegraph